LUBBOCK, Texas, Sept. 27, 2012 /PRNewswire/ -- Positron
Corporation (OTCBB:POSC), a molecular imaging healthcare company
will be presenting at the 1st International Business
Conference for Producers, Suppliers and Consumers of Isotope
Products (1IBCI), which will take place in Moscow, Russia, October
1st - 3rd, 2012.
The 1IBCI conference, organized by Isotope Co., an entity within
the Rosatom State Atomic Energy Corporation's (ROSATOM) Program
"Radiation Technologies," will focus on the business and scientific
issues, plans and perspectives of the world isotope industry.
The conference will be attended by the scientific community
made up of key isotope market players and experts from various
countries that will discuss the latest trends, global isotope
consumption & market development, isotope production &
supply, applications, products and devices in the industry. The
conference is expected to give a new impetus to the international
cooperation in the sphere of isotope applications and will
facilitate the entire industry entering a qualitatively new level
of development.
ROSATOM incorporates a vast number of scientific institutions in
the world market of nuclear technologies. ROSATOM links
manufacturers and consumers of isotope products in both domestic
and foreign markets.
Jason Kitten, President of
Manhattan Isotope Technology a subsidiary of Positron Corporation,
was invited to speak on the topic of Nuclear Medicine Trends. "This
conference is key in connecting and collaborating with the
strategic global isotope players and enables Positron to establish
itself and our business opportunities on a world stage with most
all of the leading isotope producing organizations."
About Positron: Positron Corporation is a molecular
imaging healthcare company vertically integrating all the segments
of nuclear cardiology—providing an end-to-end solution for cardiac
PET. Through proprietary PET imaging systems,
radiopharmaceuticals and radioisotopes, Positron enables healthcare
providers to more accurately diagnose disease and improve patient
outcomes, while practicing cost effective medicine. Positron's
unique products, market position and approach in securing the
supply chain are substantial advantages, further accelerating the
adoption of cardiac PET and growth of nuclear cardiology.
Positron is redefining the industry. More information about
Positron is available at www.positron.com.
Forward Looking Statements: Statements in this
document contain certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, as amended. These
statements are based on many assumptions and estimates and are not
guarantees of future performance. These statements may involve
known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of Positron
Corporation to be materially different from future results,
performance or achievements expressed or implied by such
forward-looking statements. Positron assumes no obligation to
publicly update or revise these forward-looking statements for any
reason, or to update the reasons actual results could differ
materially from those anticipated in these forward-looking
statements, even if new information becomes available in the
future. Our actual results may differ materially from the
results anticipated in these forward-looking statements due to a
variety of factors, including, without limitation those set forth
as "Risk Factors" in our filings with the Securities and Exchange
Commission.
SOURCE Positron Corporation